Close Menu
Home › Foundation Medicine, Natera to Develop Liquid Biopsy Monitoring Assays

Foundation Medicine, Natera to Develop Liquid Biopsy Monitoring Assays

Sep 24, 2019
|
staff reporter

This article has been updated with financial and other details from a Natera regulatory filing.

NEW YORK – Foundation Medicine and Natera said today that they will jointly develop and commercialize personalized circulating tumor DNA monitoring assays for biopharmaceutical and clinical customers who order the FoundationOne CDx test.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Dec
19
Featured Webinar

Evolution of Tumor Profiling in a Clinical Lab: Moving toward Comprehensive Genomic Profiling

Sponsored by
Qiagen

This webinar will provide a first-hand look at how a clinical lab evolved its tumor profiling workflow from a targeted panel approach toward comprehensive genomic profiling.  

Jan
28
Featured Webinar

Comprehensive Profiling of Myeloid Malignancies with Reliable Detection of FLT3 and CEBPA

Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

What's Popular?

In Molecular Diagnostics

  1. NCCN Updates Genetic Testing Guidelines for Assessing Breast, Ovarian, Pancreatic Cancer Risk

  2. Hologic Vaginitis Tests Offer Improvements Over Gold Standard Methods

    Premium

  3. FDA Approves Foundation Medicine CDx for Novartis Breast Cancer Drug Piqray

  4. Illumina, ArcherDx Expand Partnership on NGS IVD Tests

  5. BioMérieux, Beckman Coulter, Siemens Healthineers, Others Get 510(k) Clearances in November

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.